Insmed CEO reveals Japan patient population exceeds US market for lung disease

• Insmed (INSM) announced affirmative Phase 3b results for ARIKAYCE arsenic first-line MAC lung illness therapy, perchance expanding its addressable marketplace from 30,000 to implicit 200,000 patients, with a supplemental FDA filing planned for the 2nd fractional of 2026. Japan contributed much than a 4th of ARIKAYCE’s planetary revenues and grew 40% successful 2025, importantly outpacing U.S. maturation of 7.7% to 14.1%, driven by a diligent colonisation larger than the full United States.

• Insmed’s dual-blockbuster structure—BRINSUPRI connected gait for $1B+ successful 2026 and ARIKAYCE astatine $450-470M—positions the institution for a 2027 gross ramp if the statement enlargement wins FDA support and launches internationally.

• Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin discontinue earlier than expected.

Here is simply a information that should reframe however you deliberation astir Insmed (NASDAQ:INSM) and its lung illness franchise: Japan has much patients with MAC lung illness than the full United States.

That came straight from CEO Will Lewis successful a caller interview. "There are really much patients successful Japan that person this illness than determination are successful each of the United States. So it's a precise important marketplace arsenic well."

That azygous enactment reframes the concern thesis considerably.

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

ARIKAYCE, Insmed's inhaled amikacin therapy, is presently approved to dainty the refractory signifier of MAC lung disease, meaning patients who person already failed modular antibiotic therapy. That addressable marketplace sits astatine astir 30,000 patients.

The ENCORE Phase 3b trial, which announced affirmative results connected March 23, 2026, gathering its superior and each secondary endpoints, tested ARIKAYCE arsenic a first-line operation therapy alongside modular antibiotics. The results showed improvements successful grounds scores, civilization conversion (eradication of the underlying infection), and faster and much durable outcomes.

If the statement expands to see first-line treatment, the full addressable marketplace grows from 30,000 to much than 200,000 patients. That is not a humble step-up. It is simply a class transformation.

Insmed plans to record a supplemental NDA with the FDA successful the 2nd fractional of 2026, simultaneously filing successful Japan. The afloat commercialized interaction of the statement enlargement is expected to materialize successful 2027.

The Japan accidental is not hypothetical. The marketplace is already producing. Japan delivered 40% maturation successful 2025 compared to 2024 and contributed much than a 4th of ARIKAYCE's planetary revenues. In the quarters starring into that, Japan was increasing adjacent faster: 48.3% year-over-year successful Q1 2025 and 45.3% successful Q2 2025.